Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23923
Title: The value of 18F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.
Austin Authors: Ayati, Narjess ;Sadeghi, Ramin;Kiamanesh, Zahra;Lee, Sze Ting ;Zakavi, S Rasoul;Scott, Andrew M 
Affiliation: Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Issue Date: Feb-2021
metadata.dc.date: 2020-07-29
Publication information: European Journal of Nuclear Medicine and Molecular Imaging 2021; 48(2): 428-448
Abstract: To investigate the ability of 18F-FDG PET/CT to assess the response of patients with metastatic melanoma to immunotherapy. A comprehensive search of the literature for studies examining the prognostic value of 18F-FDG PET/CT in monitoring the response of patients with metastatic melanoma to immunotherapy was performed. We also screened the references of the selected articles to identify any other relevant studies. Detailed data were extracted and categorized. Comprehensive meta-analysis software was used for analysis. Twenty four eligible articles were included in the systematic review. Based on the baseline 18F-FDG PET/CT imaging, the pooled hazard ratios of MTV, SLR, SUV/SULmax, SUV/SULpeak, and TLG for overall survival (OS) were 1.777 (95%CI: 1.389-2.275, p < 0.001), 3.425 (95%CI: 1.707-6.869, p = 0.001), 0.941 (95%CI: 0.599-1.477, p = 0.791), 1.704 (95%CI: 1.253-2.316, p = 0.016), and 1.755 (95%CI: 1.315-2.342, p < 0.001), respectively. The conventional and modified response assessment criteria exhibited a pooled sensitivity of 64% (95%CI: 46-79%) and 94% (95%CI: 81-99%) and a pooled specificity of 80% (95%CI: 59-93%) and 84% (95%CI: 64-95%), respectively, for the early 18F-FDG PET/CT scan. On the other hand, based on the late 18F-FDG PET/CT scan, the pooled sensitivity of 67% (95%CI: 35-90%) and 92% (95%CI: 73-99%) and pooled specificity of 77% (95%CI: 56-91%) and 76% (95%CI: 50-93%) were observed for the conventional and modified criteria, respectively. PET-detectable immune-related adverse events (irAEs) were associated with the response to therapy. The baseline SUVpeak, MTV, and TLG parameters represent promising predictors of the final response of metastatic melanoma patients to immunotherapy. Modified response assessment criteria are potentially an appropriate method for monitoring immunotherapy. irAEs are also valuable for predicting eventual clinical benefit of treatment.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23923
DOI: 10.1007/s00259-020-04967-9
ORCID: 0000-0002-6656-295X
PubMed URL: 32728798
Type: Journal Article
Subjects: 18F-FDG PET/CT imaging
Immune checkpoint inhibitor
Immunotherapy
Melanoma
Response assessment
Appears in Collections:Journal articles

Show full item record

Page view(s)

16
checked on Jul 2, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.